Evaluating patient experience and healthcare utilisation in cytoreductive surgery and hyperthermic intraperitoneal chemotherapy

被引:0
|
作者
Siu, Adrian [1 ,2 ]
Steffens, Daniel [1 ,2 ]
Ansari, Nabila [1 ,3 ]
Karunaratne, Sascha [1 ,2 ]
Solanki, Henna [1 ]
Ahmadi, Nima [1 ,3 ]
Solomon, Michael [1 ,2 ,3 ]
Koh, Cherry [1 ,2 ,3 ]
机构
[1] CO Royal Prince Alfred Hosp, Surg Outcomes Res Ctr SOuRCe, POB M157,Missenden Rd, Camperdown, NSW 2050, Australia
[2] Univ Sydney, Fac Med & Hlth, Cent Clin Sch, Sydney, NSW, Australia
[3] Royal Prince Alfred Hosp, Dept Colorectal Surg, Sydney, NSW, Australia
关键词
cytoreductive surgery; geographic disparity; healthcare equity; healthcare utilisation; hyperthermic intraperitoneal chemotherapy; patient experience; peritoneal malignancies; surgical oncology; HIPEC;
D O I
10.1071/AH24192
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Objective. Approximately 30% of Australians reside in rural communities, where accessing healthcare facilities can be challenging due to considerable distance. This can result in disparities in healthcare equity, subsequently increasing risk of adverse health outcomes, delayed diagnosis, and diminished quality of life. These geographical constraints may be exacerbated in advanced cancers for which treatment is available only at selected centres with appropriate expertise. The aim of this study was therefore to explore the impact of patient residence on experience and healthcare utilisation following cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). Methods. A retrospective study examined consecutive CRS and HIPEC patients at Royal Prince Alfred hospital from 2017 to 2022. Patients were stratified as metropolitan and regional based on their postcode. Demographics, experiential, and healthcare utilisation data were collected at multiple time points. Statistical analysis included chi-squared and T-tests. Results. Of the 317 participants, 228 (72%) were from metropolitan and 89 (28%) from regional areas. Regional patients tended to rate their hospital experience as 'very good' (P = 0.016). Metropolitan patients were more compliant with surgical follow-up (P < 0.001). No other differences were observed in patient characteristics, experience or healthcare utilisation. Conclusions. The geographical location of patients undergoing CRS and HIPEC for peritoneal malignancies at a major tertiary referral centre did not significantly influence their experience or healthcare utilisation outcomes. Future studies should evaluate long-term healthcare service utilisation or the ramifications of reduced follow-up on recurrence and survival, which will contribute to a deeper understanding of resource allocation in metropolitan and regional Australia, and illuminate its impact on clinical outcomes.
引用
收藏
页数:12
相关论文
共 50 条
  • [31] EVALUATING THE EFFECTS OF TIVA ON POSTOPERATIVE PAIN AFTER CYTOREDUCTIVE SURGERY WITH HYPERTHERMIC INTRAPERITONEAL CHEMOTHERAPY
    Soliz, J.
    Owusu-Agyemang, P.
    Cata, J. P.
    Zavala, A. M.
    Fournier, K.
    Hernandez, M.
    Hayes-Jordan, A.
    Rahlfs, T. F.
    Gottumukkala, V.
    ANESTHESIA AND ANALGESIA, 2016, 123 : 802 - 803
  • [32] Role of Imaging Studies in Evaluating Patients Post Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy
    Fayed, Mohamed
    Angappan, Santhalakshmi
    Oyibo, Oghenekpaobor
    Valliani, Arif
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2021, 13 (12)
  • [33] Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for the Treatment of Peritoneal Carcinomatosis: Our Initial Experience
    Bartos, Adrian
    Bartos, Dana
    Raluca, Stoian
    Mitre, Calin
    Hadade, Adina
    Iancu, Ioana
    Cioltean, Cristian
    Iancu, Cornel
    Militaru, Claudia
    Parau, Angela
    Breazu, Caius
    CHIRURGIA, 2019, 114 (02) : 222 - 233
  • [34] Cytoreductive Surgery and Intraperitoneal Hyperthermic Chemotherapy (HIPEC) by Minimally Invasive Approach, an Initial Experience
    Arjona-Sanchez, A.
    Rufian-Pena, S.
    Sanchez-Hidalgo, J. M.
    Casado-Adam, A.
    Cosano-Alvarez, A.
    Briceno-Delgado, J.
    WORLD JOURNAL OF SURGERY, 2018, 42 (10) : 3120 - 3124
  • [35] Cytoreductive surgery and intraperitoneal hyperthermic chemotherapy for peritoneal surface malignancy: Experience with 501 procedures
    Levine, Edward A.
    Stewart, John H., IV
    Russell, Gregory B.
    Geisinger, Kim R.
    Loggie, Brian L.
    Shen, Perry
    JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, 2007, 204 (05) : 943 - 953
  • [36] Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in appendix cancer A single-center experience
    Yuksel, Cemil
    Basceken, Salim Ilksen
    Ersen, Ogun
    Culcu, Serdar
    Mercan, Umit
    Bakirarar, Batuhan
    Unal, Ali Ekrem
    ANNALI ITALIANI DI CHIRURGIA, 2022, 93 (05) : 584 - 591
  • [37] Cytoreductive Surgery and Intraperitoneal Hyperthermic Chemotherapy (HIPEC) by Minimally Invasive Approach, an Initial Experience
    A. Arjona-Sanchez
    S. Rufian-Peña
    J. M. Sanchez-Hidalgo
    A. Casado-Adam
    A. Cosano-Alvarez
    J. Briceño-Delgado
    World Journal of Surgery, 2018, 42 : 3120 - 3124
  • [38] Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Recurrent Ovarian Cancer - An Asian Experience
    Chia, C. S.
    Tan, G.
    Tham, C.
    Soo, K.
    Teo, M.
    ANNALS OF SURGICAL ONCOLOGY, 2013, 20 : S111 - S111
  • [39] Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) in a patient with peritoneal mesothelioma and HIV infection
    Balestra, Maria Rosaria
    Baratti, Dario
    Crippa, Fulvio
    Laterza, Barbara
    Kusamura, Shigeki
    Langer, Martin
    Deraco, Marcello
    TUMORI JOURNAL, 2010, 96 (02): : 340 - 344
  • [40] Quality and readability assessment of online patient information on cytoreductive surgery and hyperthermic intraperitoneal chemotherapy
    Rouhi, Armaun D.
    Ghanem, Yazid K.
    Hoeltzel, Gerard D.
    Miura, John T.
    Aarons, Cary B.
    Williams, Noel N.
    Dumon, Kristoffel R.
    Karakousis, Giorgos C.
    JOURNAL OF SURGICAL ONCOLOGY, 2023, 127 (04) : 699 - 705